Norwegian Institute of Public Health, Bergen, Norway.
Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.
BMJ Open. 2022 May 11;12(5):e054840. doi: 10.1136/bmjopen-2021-054840.
The 'Outcomes & Multi-morbidity in Type 2 Diabetes' (OMIT) is an observational registry-based cohort of Norwegian patients with type 2 diabetes (T2D) established to study high-risk groups often omitted from randomised clinical trials.
The OMIT cohort includes 57 572 patients with T2D identified via linkage of Norwegian Diabetes Register for Adults and the Rogaland-Oslo-Salten-Akershus-Hordaland study, both offering data on clinical patient characteristics and drug prescriptions. Subsequently these data are further linked to the Norwegian Prescription Database for dispensed medications, the Norwegian Population Register for data on death and migration, Statistics Norway for data on socioeconomic factors and ethnicity and the Norwegian Directorate of Health for data on the general practices and clinical procedures involved in the care of cohort patients. OMIT offers large samples for key high-risk patient groups: (1) young-onset diabetes (T2D at age <40 years) (n=6510), (2) elderly (age >75 years) (n=15 540), (3) non-Western ethnic minorities (n=9000) and (4) low socioeconomic status (n=20 500).
On average, patient age and diabetes duration is 67.4±13.2 and 12.3±8.3 years, respectively, and mean HbA for the whole cohort through the study period is 7.6%±1.5% (59.4±16.3 mmol/mol), mean body mass index (BMI) and blood pressure is 30.2±5.9 kg/m and 135±16.1/78±9.8 mm Hg, respectively. Prevalence of retinopathy, coronary heart disease and stroke is 10.1%, 21% and 6.7%, respectively.
The OMIT cohort features 5784 subjects with T2D in 2006, a number that has grown to 57 527 in 2019 and is expected to grow further via repeated linkages performed every third to fifth year. At the next wave of data collection, additional linkages to Norwegian Patient Registry and Norwegian Cause of Death Registry for data on registered diagnoses and causes of death, respectively, will be performed.
“2 型糖尿病结局和合并症（OMIT）”是一个基于观察性注册的挪威 2 型糖尿病（T2D）患者队列，旨在研究经常被随机临床试验排除的高危人群。
OMIT 队列包括通过成人挪威糖尿病登记处和罗加兰-奥斯陆-萨尔滕-阿克什胡斯-霍达兰研究的链接确定的 57572 名 T2D 患者，这两项研究均提供了临床患者特征和药物处方的数据。随后，这些数据进一步与挪威处方数据库中开出的药物、挪威人口登记处中关于死亡和移民的数据、挪威统计局中关于社会经济因素和种族的数据以及挪威卫生部中关于参与队列患者护理的一般实践和临床程序的数据进行了链接。OMIT 为关键的高危患者群体提供了大量样本：（1）年轻起病的糖尿病（T2D 发病年龄<40 岁）（n=6510），（2）老年患者（年龄>75 岁）（n=15540），（3）非西方少数民族（n=9000）和（4）社会经济地位低（n=20500）。
平均而言，患者年龄和糖尿病病程分别为 67.4±13.2 岁和 12.3±8.3 年，整个队列在研究期间的平均 HbA1c 为 7.6%±1.5%（59.4±16.3mmol/mol），平均体重指数（BMI）和血压分别为 30.2±5.9kg/m 和 135±16.1/78±9.8mmHg。视网膜病变、冠心病和中风的患病率分别为 10.1%、21%和 6.7%。
OMIT 队列最初于 2006 年纳入 5784 例 T2D 患者，到 2019 年已增加至 57527 例，预计通过每三至五年进行一次的重复链接，其规模还将进一步扩大。在下一次数据收集时，将对挪威患者登记处和挪威死因登记处进行链接，以获取登记诊断和死因的数据。
